Best Adenoviral Vector CDMOs in Germany
· updated as new inspection, certificate, and trial data enters the platform
1
CDMOs tracked
0
Fully scored
Adenoviral vector CDMOs make replication-deficient adenovirus for gene therapy and vaccines, using producer cell lines (e.g. HEK293), suspension bioreactors, and chromatographic purification. The platform reaches high titers, which suits vaccine-scale demand.
Selecting an adenoviral CDMO turns on serotype and producer-line experience, suspension scale, full/empty particle control, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
Last updated 2026-07-11. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| — |
IDT Biologika GmbH
Dessau-Roßlau, Germany
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Adenoviral Vector CDMO
Producer line & serotype
Confirm experience with your serotype (Ad5 and others) and producer cell line, and whether the process is suspension-adapted for scale.
Scale & titer
Adenovirus reaches high titers for vaccine-scale demand. Match validated bioreactor scale to your dose and volume.
Particle quality
Full/empty particle ratio and aggregate control affect potency and safety. Ask about the analytics package.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
What makes the German CDMO cluster distinctive within Europe?
Germany's CDMO base combines three attributes that shape sponsor decisions: (1) strong biologics + advanced-therapy depth — BioNTech's Marburg site is one of the largest single-facility mRNA operations globally, Boehringer Ingelheim BioXcellence operates commercial-scale biologics at Biberach, and Rentschler carries deep mAb + biosimilar experience; (2) engineering discipline — German pharmaceutical manufacturing has a reputation for process rigor that translates into strong FDA and EMA inspection outcomes; (3) proximity to European pharmaceutical R&D centers, which reduces tech-transfer coordination cost. German CDMOs generally hold BfArM + EMA + MHRA + FDA certifications concurrently for global-market-supplying facilities.
Which German CDMOs specialize in advanced-therapy modalities (viral vector, cell therapy, mRNA)?
Germany hosts substantial advanced-therapy CDMO capacity. Cross-reference with modality pages to filter: mRNA CDMOs (BioNTech Manufacturing Services is Germany's largest), AAV CDMOs, lentiviral CDMOs, cell therapy CDMOs, or the viral vector umbrella. The individual CDMO profile pages surface facility-level modality coverage — critical for advanced-therapy programs where the specific German site's containment class and analytics platform matter more than country-level aggregates.
German CDMOs supplying US and Asian markets
German CDMOs with FDA and Asian regulator inspection history qualify to supply global markets; those without cross-jurisdictional inspection posture are typically limited to EU and MHRA scope. Cross-check with the US region ranking and Asia region ranking to identify German-headquartered CDMOs with global footprint. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so cross-jurisdictional German CDMOs typically rank higher on this pillar than EU-only competitors.
Adenoviral Vector CDMOs — Frequently Asked Questions
What should I look for in an adenoviral vector CDMO?
Confirm serotype and producer-line experience, a suspension process at your required scale, strong particle-quality analytics, and a clean FDA and EMA/MHRA record.
How is adenoviral vector manufacturing different from AAV?
Both are non-enveloped viral vectors made in HEK293-type lines, but adenovirus is larger and drives strong transient expression (suiting vaccines), while AAV is the workhorse for durable in vivo gene therapy.
Related modalities